Jeff Mirviss is presently EVP and president of the Peripheral Interventions Division at Boston Scientific. He was already an independent director on Boston-based Day Zero Diagnostics’ board.
“Jeff has been an important advisor, investor and supporter of DZD since the early days of our company and the company has benefitted greatly from his involvement and counsel,” said Jong Lee, CEO and co-founder of Day Zero Diagnostic.
Lee added in the news release: “Jeff’s wealth of experience in strategic investments and corporate transactions in the medtech space will be incredibly valuable as we get closer to commercialization of our first-of-its-kind diagnostic and expand long-term strategic partnerships with key industry players.”
Mirviss thinks Day Zero Diagnostics’ technology could transform patient care. “Their platform technology will usher in a new era of rapid diagnostics for the hospital microbiology lab that brings the full power of next-generation sequencing into clinical practice.”
Day Zero Diagnostics seeks to blaze a trail with a diagnostic tool that identifies a myriad of bacterial and fungal pathogens and gauges their antimicrobial susceptibility — all within an eight-hour timeframe. In contrast, according to the company, present-day antimicrobial resistance tests take significantly longer.
Antimicrobial-resistant infections were associated with nearly 5 million deaths worldwide in 2019, according to the CDC.
